Oncology Brothers
@oncbrothers.bsky.social
Practice changing discussions by community oncologists: Drs. Rohit Gosain & Rahul Gosain. OwnViews/Not a Medical Advice. COI http://bit.ly/3o9agL3 Web: http://oncbrothers.com
Thrilled to announce our Annual Meeting Featured Voices! Get ready for a wealth of expert perspectives and engaging discussions throughout the meeting. Don't miss out – follow along and contribute to the conversation using the official hashtag: #ASCO25
Hot off the press in @ascocancer.bsky.social journal JCO Oncology Advances: Immune Checkpoint Blockade Therapies for Colorectal Cancer: Current Strategies and Emerging Approaches ascopubs.org/doi/10.1200/... from our University of Minnesota group led by Dr. Ajay Prakash - #Immunoonc #immunotherapy
Immune Checkpoint Blockade Therapies for Colorectal Cancer: Current Strategies and Emerging Approaches | JCO Oncology Advances
There have been significant advances in colorectal cancer (CRC) immunotherapy over the past decade, with incorporation into both the metastatic and adjuvant/neoadjuvant treatment spaces. However, ther...
ascopubs.org
HER2 in NSCLC is underrecognized & complex. Grateful to join @cor2edmeded.bsky.social with an expert path colleague to discuss timely testing and clinical utility—now targetable on/off clinical trials. Thanks @oncbrothers.bsky.social for the invite! #lcsm #oncMedEd cor2ed.com/lung-connect...
The HER2 diagnostic and treatment landscape in NSCLC: Episode 1 | COR2ED
This is the first episode of a two-part series on the HER2 diagnostic and treatment landscape in non-small cell lung cancer (NSCLC), hosted by the
cor2ed.com
#Cabozantinib is now approved in #NET based off #CABINET study! We discussed the design, findings, sequencing, and AEs with Dr. Aman Chauhan (full discussion and one page takeaway 👇👇) Full 🗣️: ⭐️ Oncbrothers.com/cabinet ⭐️ Also on the “Oncology Brothers” podcast #OncSky #MedSky #GiOnc
I recently had the privilege of joining the @oncbrothers.bsky.social to discuss all things #PancreaticCancer, including current and emerging treatment options that are bringing hope for better outcomes for patients. Many thanks👊 oncbrothers.com/pancreatic-a... www.cancernetwork.com/treatment-al...
Less than 2 months to #ASCO25! Join us to discuss the current SoC➕how the data from #ASCO25 will change/reinforce our practice! ⭐️ InPerson: May 31st, 2025 ⭐️ Location📍Marriott Marquis ⭐️ Time: 6:30-9:00PM ⭐️ Register bit.ly/aioasco25 #AdvInOnc25 #OncSky
#Zolbetuximab was approved based off #GLOW & #SPOTLIGHT (one page/slide summary attached)! We discussed the design, findings, sequencing and AEs/management w/ #KoheiShitara Full Discussion: ⭐️ Oncbrothers.com/zolbetuximab... ⭐️ Also on the “Oncology Brothers” podcast #gism #CanSky #OncSky
Treatment Algorithm series: discussion on HER2+ #BreastCancer ✅ APT data/TCHP ✅ Metastatic disease ✅ Her2/ER/PR+ Full discussion: ⭐️ oncbrothers.com/her2positive... ⭐️ www.cancernetwork.com/treatment-al... ⭐️ “Oncology Brothers” podcast #bcsm #CancerSky #OncSky @drsarahsammons.bsky.social
What is Dr. Brian Betts most excited about for #TANDEM25? 🥁 Learn more about Roswell Park's involvement: www.roswellpark.org/newsroom/202...
Publication by @ascocancer.bsky.social on academic medical oncology. Makes me wonder- how do we encourage more transparency among institutions to set these standards ? ascopubs.org/doi/10.1200/...
Promoting Reasonable Career Expectations and Maximizing Professional Fulfillment for Academic Oncologists: ASCO Recommendations for Academic Medical Centers
In this statement, ASCO encourages academic medical centers to change their policies and expectations to enhance and promote the professional fulfillment of academic medical oncologists. The statement...
ascopubs.org
As @asco #GU25 approaches worth considering again the true value of Progression Free Survival (#PFS) endpoints in #ProstateCancer www.nature.com/articles/s41...
Treatment Algorithm series: starting off w/ TNBC discussion @vkaklamani.bsky.social ✅ Early disease ✅ ≥T2 or N+ disease ✅ Metastatic disease ✅ Low ER/PR+ Full 🗣️: ⭐️ oncbrothers.com/how-to-treat... ⭐️ www.cancernetwork.com/treatment-al... ⭐️ “Oncology Brothers” podcast #bcsm #BreastCancer
The #GU25 abstracts are now available! Late-Breaking Abstracts (LBAs) will be released at 7:00 AM PT on their day of presentation. Check out the latest practice-changing science in GU cancers here: brnw.ch/21wQBxm Co-sponsored by @astro-org.bsky.social and Society of Urologic Oncology
🚨In <1 wk, it’s #GU25🚨 Let’s discuss the current SoC ➕ how the data will change/reinforce our practice at #AdvInOnc25: - Bladder Ca - Prostate Ca - RCC *Join us LIVE* 📅 Date: Feb 12, 2025 ⏰ Time: 6:00-8:00PM 📝 bit.ly/guaio25 #OncSky #MedSky #gusm #Oncology #Cancer #CanSky
AMPLIFY for 1L CLL now in @nejm.org 🔑 takeaways: 1️⃣ Fixed-duration #acalabrutinib + #venetoclax (±obinutuzumab) improved PFS (3-year): 76% (A+V), 83% (AVO) vs 66% (Chem) 2️⃣ AVO showed deeper responses but higher infection risk 3️⃣ New SoC for many #OncSky #CanSky #HemeSky
Recognizing the brilliant #WomenInMedicine today 2/3/25 who continue to persevere, break glass ceilings and improve healthcare #NWPD25 #IamBlackwell @quirogad.bsky.social @aryaroy.bsky.social @nerealliamd.bsky.social @drsgraff.bsky.social @drsarahsammons.bsky.social @maryamlustberg.bsky.social
Nice discussion on management of intermediate risk #HCC hosted by @oncbrothers.bsky.social! Cc: @markyarchoan.bsky.social #liversky #oncsky oncbrothers.com/liver-2024-4
Intermediate HCC – the evolving role of Immunotherapy with Multimodality approaches
oncbrothers.com
T-DXd approved today after progression on CDK4/6 inhibitor for HR+ HER2-low and HER2-ultralow metastatic breast cancer based on results of DESTINY-Breast06. #bcsm #oncsky
Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies
astrazeneca.com
T-Dxd approved as first line chemo in HR+, HER2 low or ultra low disease. Do all patients need it first line? Probably not. But great option for higher risk. #bcsm #oncosky
Elisabetta Bonzano MD, PhD@elisabettabonzano.bsky.social · 2y ago📌 Enhertu approved in the US as first HER2-directed therapy for patients with HER2-low or HER2-ultralow metastatic breast cancer following disease progression after one or more endocrine therapies www.astrazeneca.com/media-centre... @oncoalert.bsky.social
🔥🔥🔥BREAKWATER🔥🔥🔥 BRAF V600E mut #CRC SOC (FOLFOX) +/- encorafenib + cetuximab EC + FOLFOX shows: ✅⬆️ORR ✅Strong suggestion of ⬆️OS 🚨EC + FOLFOX is a new SOC‼️ Pub available: idp.nature.com/authorize?re... #GI25 @ascocancer.bsky.social
#GI25 highlights #CommunityOnc: 1. #SCIENCE: Adv Eso SCC 2. #ESOPEC publication (Eso/GEJ/Ga) 3. Chemo in resectable Panc Ca 4. #StarterNET: GEP-NET 5. #CM8HW: dMMR/MSI-H mCRC 6. #BREAKWATER: BRAFV600E mCRC 7. ctDNA: #BESPOKE + SWOG80702 #OncSky #gism @ascocancer.bsky.social 1/8
Join us for Intersections: Personalized Risk Assessment for Gastrointestinal Cancers with Mary Uan-Sian Feng, MD. Gain insights on risk scores, biomarkers for screening, and more cutting-edge updates at #GI25!
5/20 #TumorBoardTuesday 👩⚕️Mini Tutorial 2👩⚕️ Pt characteristics in INAVO120: No prior treatment for ABC PIK3CA mut a1c≤6.0, fasting BG<126 ~Half with ≥3 involved organ sites ~Half with liver involvement, ~40% with 🫁 involvement ~1/3 with 1° endocrine resistance, 2/3 with 2° @dr-rshatsky.bsky.social
Who has tried to add Palbo to maintenance let + HP? Know it isn't "approved yet", but wasn't successful. Anyone been successful for coverage yet with #PATINA? @ptarantinomd.bsky.social @hoperugo.bsky.social @stolaney1.bsky.social @vkaklamani.bsky.social @jochien.bsky.social
#GISeries: #Zanidatamab was recently approved based off #HerizonBTC01! We 🗣️ design, findings, sequencing and AEs/management with Dr. Shubham Pant Full Discussion: - Oncbrothers.com/zanidatamab-... - Also on the “Oncology Brothers” podcast #OncSky #MedSky #gism #GI25
Adjuvant IO trials in muscle-invasive urothelial carcinoma: IMvigor010: Atezo DFS HR 0.89, OS HR 0.85. CheckMate 274: Nivo DFS HR 0.71, OS HR 0.76. AMBASSADOR: Pembro DFS HR 0.73, OS HR 0.98. #oncology #cancer @oncoalert.bsky.social @oncbrothers.bsky.social @erplimackmd.bsky.social @nejm.org
Early-onset colorectal cancer (<50 yrs) is rising, linked to factors like Western diets, obesity, and gut microbiota changes. Prevention & early detection strategies are vital. #ColorectalCancer #Oncology #CancerPrevention @oncoalert.bsky.social @oncbrothers.bsky.social rdcu.be/d49OZ
